Pfizer launches a new drug in the UAE against Gram-negative bacteria

Pfizer announced the launch of a new medicine in the UAE intended for adult patients suffering from serious bacterial infections caused by Gram-negative bacteria.

Antibiotic resistance occurs when bacteria lose their response to available medications, making infection control more complex and increasing the likelihood of serious complications.

Resistant infections caused by Gram-negative bacteria pose an extremely serious challenge, as they limit effective treatment options, lengthen patients’ stay in hospitals, and exacerbate the health and psychological suffering of those infected and their families.

This advanced treatment represents a pivotal addition to the therapeutic system, as it restores effectiveness against the most resistant pathogens, and gives doctors a long-awaited tool for treating stubborn infections.

Serhat Yalcinkaya, President of Pfizer in the Gulf Region, said: “At Pfizer, the patient remains at the heart of our vision and mission. This development embodies our firm commitment to our scientific and humanitarian responsibility, and our constant pursuit of creating medical solutions that make a real impact on the lives of patients and communities. For more than 175 years, Pfizer has dedicated its efforts to being at the forefront of the fight against infectious diseases, and our continued focus on antibiotic resistance is an extension of this approach. We are proud to strengthen Our partnerships with healthcare providers and government agencies in the UAE, to work together to ensure that patients have access to life-saving treatments today, and to maintain their effectiveness for the benefit of future generations.”